Pitcairn’s Iovance Biotherapeutics IOVA Stock Holding History

Pitcairn’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,502	Closed	-$101K	–	595
2022 Q3	$101K	Sell	10,502 -782	-7%	-$9.02K	0.01%	558
2022 Q2	$125K	Buy	+11,284	New	+$148K	0.01%	566

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pitcairn's IOVA Position: Q4 2022 in Review

Pitcairn sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 10,502 shares — an estimated $101K sold.

Pitcairn first reported a position in IOVA in Q2 2022 and held it in 2 quarters. The position peaked at $125K in Q2 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Pitcairn reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Pitcairn sold 10,502 Iovance Biotherapeutics shares in Q4 2022, an estimated $101K.
Pitcairn first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 2 quarters.
Pitcairn's Iovance Biotherapeutics position peaked at $125K in Q2 2022.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Pitcairn's 13F filing for Q4 2022, filed 13 Feb 2023.